At present, three randomized controlled trials (NCT 04341935, NCT 04371978 and NCT04365517) (Retrieved from: https://clinicaltrials.gov/) were ongoing to study the effect of DPP4 inhibitors on the prognosis of COVID-19 and the clinical results were expected to be obtained as soon as possible. The gene discussed is DPP4; the disease is COVID-19.